Specific considerations in the treatment of pediatric inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 1, 2008, Pages 105-124

  Grossman, Andrew B ^a   Baldassano, Robert N ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Children; Crohn's disease; Inflammatory bowel disease; Pediatric; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CALCIUM; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; FISH OIL; FRUCTOSE OLIGOSACCHARIDE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; OMEGA 3 FATTY ACID; PLACEBO; PREBIOTIC AGENT; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; RIFAXIMIN; SALAZOSULFAPYRIDINE; STEROID; UNINDEXED DRUG; VSL3;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ALLERGIC PNEUMONITIS; ANTIINFLAMMATORY ACTIVITY; BLOODY DIARRHEA; BONE DEMINERALIZATION; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COLON RESECTION; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DELAYED PUBERTY; DIARRHEA; DIETARY INTAKE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERIC FEEDING; ENTERITIS; FIRST PASS EFFECT; GENE MUTATION; GENETIC PREDISPOSITION; GROWTH DISORDER; HALITOSIS; HEARTBURN; HEPATITIS; HUMAN; ILEITIS; INCIDENCE; INFECTION; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; MONOTHERAPY; NAUSEA; NONHUMAN; ONSET AGE; OSTEOPENIA; PANCREATITIS; PATHOGENESIS; PATIENT COMPLIANCE; PERICARDITIS; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PREVALENCE; PROCTOCOLECTOMY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SYMPTOM; TASTE DISORDER; TERATOGENICITY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VOMITING;

ADOLESCENT; CHILD; CHILD NUTRITION DISORDERS; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE;

EID: 49149097896     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.1.105     Document Type: Review

References (182)

1. Loftus CG, Loftus EV Jr, Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm. Bowel Dis. 13(3), 254-261 (2007).
2. Kucharzik T, Maaser C, Lugering A et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm. Bowel Dis. 12(11), 1068-1083 (2006).
3. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol. Clin. North Am. 32(3), 967-995 (2003).
4. Heyman MB, Kirschner BS, Gold BD et al. Children with early-onset inflammatory bowel disease (IBD): analysis ofa pediatric IBD consortium registry. J. Pediatr. 146(1), 35-40 (2005).
5. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411(6837), 599-603 (2001).
6. Alvarez-Lobos M, Arostegui JI, Sans M et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann. Surg. 242(5), 693-700 (2005).
7. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804), 1461-1463 (2006).
8. Tremelling M, Cummings F, Fisher SA et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 132(5), 1657-1664 (2007).
9. Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39(2), 207-211 (2007).
10. Prescott NJ, Fisher SA, Franke A et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology 132(5), 1665-1671 (2007).
11. Jacobsen BA, Fallingborg J, Rasmussen HH et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur. J. Gastroenterol. Hepatol. 18(6), 601-606 (2006).
12. Armitage E, Drummond HE, Wilson DC, Ghosh S. Increasing incidence of both juvenile-onset Crohn's disease and ulcerative colitis in Scotland. Eur. J. Gastroenterol. Hepatol. 13(12), 1439-1447 (2001).
13. Gower-Rousseau C, Salomez JL, Dupas JL et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 35(10), 1433-1438 (1994).
14. Sawczenko A, Sandhu BK, Logan RF et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 357(9262), 1093-1094 (2001).
15. Kugathasan S, Judd RH, Hoffmann RG et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr. 143(4), 525-531 (2003).
16. Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin. Gastroenterol. Hepatol. 5(12), 1424-1429 (2007).
17. Mamula P, Telega GW, Markowitz JE et al. Inflammatory bowel disease in children 5 years of age and younger. Am. J. Gastroenterol. 97(8), 2005-2010 (2002).
18. Levine A, Karban A, Eliakim R et al. A polymorphism in the INF-α promoter gene is associated with pediatric onset and colonic location of Crohn's disease. Am. J. Gastroenterol. 100(2), 407-413 (2005).
19. Meinzer U, Idestrom M, Alberti C et al. Ileal involverntiat is age dependent in pediatric Crohn's disease. Inflamm. Bowel Dis. 11(7), 639-644 (2005).
20. Levine A, Kugathasan S, Annese V et al. Pediatric onset Crohn's colitis is characterized by genotype-dependent age-related susceptibility. Inflamm. Bowel Dis. 13(12), 1509-1515 (2007).
21. Gupta N, Bostrom AG, Kirschner BS et al. Gender Differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics 120(6), E1428-E1425 (2007).
22. Turner D, Walsh CM, Benchimol EI et al. Severe paediatric ulcerative colitis: incidence, outcomes, and optimal timing for second line therapy. Gut (2007) (Epub ahead of print).
23. Urlep D, Mamula P, Baldassano R. Extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol. Dietol. 51(2), 147-163 (2005).
24. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 105(3), 681-691 (1993).
25. Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst. Rev. 3, CD003873 (2005).
26. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gatroenterology 95(6), 1523-1527 (1988).
27. Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zernel BS. Growth, body composition, and nutritional status in children and adolescents with Crohn's disease. J. Pediatr. Gastruenterol. Nutr. 31(1), 33-40 (2000).
28. Hair E, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm. Bowel Dis. 11(6), 519-527 (2005).
29. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 119(Suppl. 2), S166-S174 (2007).
30. De Benedetti F, Alonzi T, Moretta A et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99(4), 643-650 (1997).
31. Brown KA, Back SJ, Ruchelli ED et al. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients. Am. J. Gastroenterol. 97(10), 2603-2608 (2002).
32. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 126(6), 1550-1560 (2004).
33. Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 80(1), 10-15 (1981).
34. Gokhale R, Favus MJ, Karrison T et al. Bone mineral density assessment in children with inflammatory bowel disease. Grastroenterology 114(5), 902-911 (1998).
35. Semeao EJ, Jawad AF, Zemel BS et al. Bone mineral density in children and young adults with Crohn's disease. Inflamm. Bowel Dis. 5(3), 161-166 (1999).
36. Semeao EJ, Jawad AF, Stouffer NO et al. Risk factors for low bone mineral density in children and young adults with Crohn's disease. J Pediatr. 135(5), 593-600 (1999).
37. Sylvester FA, Wyzga N, Hyams JS et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 13(1), 42-50 (2007).
38. Burnham JM, Shults J, Semeao E et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am. J. Clin. Nutr. 82(2), 413-420 (2005).
39. Sentongo TA, Semaeo EJ, Stettler N et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am. J. Clin. Nutr. 76(5), 1077-1081 (2002).
40. Franchimont N, Putzeys V, Collette J et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment. Pharmacol. Ther. 20(6), 607-614 (2004).
41. Ryan BM, Russel MG, Schurgers L et al. Effect of antitumour necrosis factor-α therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment. Pharmacol. Ther. 20(8), 851-857 (2004).
42. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am. J. Gastroenterol. 100(9), 2031-2035 (2005).
43. Thearle M, Horlick M, Bilezikian JP et al. Osteoporosis: an unusual presentation of childhood Crohn's disease. J. Clin. Endocrinol. Metab. 85(6), 2122-2126 (2000).
44. Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 94(3), 603-610 (1988).
45. Fell JM, Paintin M, Arnaud-Battandier F et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment. Pharmacol. Ther. 14(3), 281-289 (2000).
46. Borrelli O, Cordischi L, Cirulli M et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4(6), 744-753 (2006).
47. Afzal NA, Davies S, Paintin M et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig. Dis. Sci. 50(8), 1471-1475 (2005).
48. Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr. 93(3), 327-335 (2004).
49. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1, CD000542 (2007).
50. Day AS, Whitten KE, Lemberg DA et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J. Gastroenterol. Hepatol. 21(10), 1609-1614 (2006).
51. Wilschanski M, Sherman P, Pencharz P et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 38(4), 543-548 (1996).
52. Berni Canani R, Terrin G, Borrelli O et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig. Liver Dis. 38(6), 381-387 (2006).
53. Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 55(3), 356-361 (2006).
54. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Ω3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2, CD006320 (2007).
55. Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of Ω3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J. Gastroenterol. 11(45), 7118-7121 (2005).
56. Bousvaros A, Guandalini S, Baldassano RN et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 11(9), 833-839 (2005).
57. Van Gossurn A, Dewit O, Louis E et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleocaecal resection. Inflamm. Bowel Dis. 13(2), 135-142 (2007).
58. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126(6), 1620-1633 (2004).
59. Lindsay JO, Whelan K, Stagg AJ et al. Clinical, microbiological, and immunological effects of fructooligosaccharide in patients with Crohn's disease. Gut 55 (3), 348-355 (2006).
60. Turner D, Steinhart AH, Griffiths AM. Ω3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3, CD006443 (2007).
61. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179), 635-639 (1999).
62. Michail S, Sylvester F, Fuchs G, Issenman R. Clinical efficacy of probiotics: review of the evidence with focus on children. J. Pediatr. Gastroenterol. Nutr. 43(4), 550-557 (2006).
63. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119(2), 305-309 (2000).
64. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124(5), 1202-1209 (2003).
65. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 118(2 Suppl. 1), S68-S82 (2000).
66. Markowitz J, Hyams J, Mack D et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin. Gastroenterol, Hepatol. 4(9), 1124-1129 (2006).
67. Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohr;s disease - evidence for and against current therapies. Aliment. Pharmacol. Ther. 25(1), 3-12 (2007).
68. Tung J, Loftus EV Jr, Freese DK et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 12(12), 1093-1100 (2006).
69. Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 24(9), 1283-1293 (2006).
70. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 4, CD000296 (2005).
71. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur. J. Gastroenterol. Hepatol. 16(1), 47-54 (2004).
72. Sandborn WJ, Lofberg R, Feagan BG et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am. J. Gastroenterol. 100(8), 1780-1787 (2005).
73. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Committee. Am. J. Gastroenterol. 99(7), 1371-1385 (2004).
74. Hyams J, Markowitz J, Lerer T et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin. Gastroenterol. Hepatol. 4(9), 1118-1123 (2006).
75. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 5(1), 103-110 (2007).
76. Gross V, Bar-Meir S, Lavy A et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment. Pharmacol. Ther. 23(2), 303-312 (2006).
77. Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm. Bowel Dis. 9(1), 34-58 (2003).
78. Zimmerman MJ, Jewell DP. Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn's disease. Aliment. Pharmacol. Ther. 10(Suppl 2), 93-98 (1996).
79. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin. Gastroenterol. Hepatol. 2(5), 379-388 (2004).
80. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst. Rev. 1, CD003715 (2005).
81. Lochs H, Mayer M, Fleig WE et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 118(2),264-273 (2000).
82. Lemann M. Review article: can post-operative recurrence in Crohn's disease be prevented? Aliment. Pharmacol. Ther. 24(Suppl. 3), 22-28 (2006).
83. Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. J. Pediatr. Gatroenterol. Nutr. 17(2), 186-192 (1993).
84. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2, CD000544 (2006).
85. Sutherland L, Macdonald JK. Oral 5-aminosalicylic add for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2, CD000543 (2006).
86. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40(6), 775-781 (1997).
87. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol. 95 (5), 1263-1276 (2000).
88. Stange EF. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Aliment. Pharmacol. Ther. 24(Suppl. 3), 64-67 (2006).
89. Velayos FS, Terdiman JP. Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. 100(6),1345-1353 (2005).
90. Ferry GD, Kirschner BS, Grand RJ et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J. Peadiatr. Gastroenterol. Nutr. 17(1), 32-38 (1993).
91. Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132(1), 66-75 (2007).
92. Lichtenstein GR, Kamm MA, Boddu P et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 5(1), 95-102 (2007).
93. West RL, van der Woude CJ, Hansen BE et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 20(11-12), 1329-1336 (2004).
94. Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis. 12(7), 651-664 (2006).
95. Prantera C, Lochs H, Campieri M et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment. Pharmacol. Ther. 23(8), 1117-1125 (2006).
96. Markowitz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am. J. Gastroenterol. 97(4), 928-932 (2002).
97. Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano, RN. Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. J. Clin. Gastroenterol. 40(2), 145-148 (2006).
98. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130(4), 1047-1053 (2006).
99. Dubinsky MC, Larnothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4), 705-713 (2000).
100. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2(9), 731-743 (2004).
101. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment. Pharmacol. Ther. 22(1), 1-16 (2005).
102. Sandborn W, Sutherland L, Pearson D et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2, CD000545 (2000).
103. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. 2, CD000067 (2000).
104. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119(4), 895-902 (2000).
105. Jeshion WC, Larsen KL, Jawad AF et al. Azathioprine and 6-mercaptopurine fbr the treatment of perianal Crohn's disease in children. J. Clin. Gastroenterol. 30(3), 294-298 (2000).
106. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 1, CD000478 (2007).
107. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 28(1), 54-58 (1999).
108. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am. J. Gatroenterol. 91(3), 423-433 (1996).
109. Grossman AB, Noble AJ, Baldassano RN. Increased dosing requirements of 6-MP and azathioprine for inflammatory bowel disease patients six years old and younger. Gastroenterology 132(4 Suppl. S1), A443-A444 (2007).
110. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease. short- and long-term toxicity. Ann. Intern. Med. 111(8), 641-649 (1989).
111. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115(4), 813-821 (1998).
112. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54(8), 1121-1125 (2005).
113. Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol. Clin. North Am. 33(2), 407-420 (2004).
114. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann. Intern. Med. 121(11), 833-841 (1994).
115. Ravikumara M, Hinsberger A, Speay CH. Role of methotrexate in the management of Crohn disease. J. Pediatr. Gastroenterol. Nutr. 44(4), 427-430 (2007).
116. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332(5), 292-297 (1995).
117. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342(22), 1627-1632 (2000).
118. Uhlen S, Belbouab R, Narebski K et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm. Bowel Dis. 12(11), 1053-1057 (2006).
119. Turner D, Grossman AB, Rosh J et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am. J. Gastroenterol 102(12), 2804-2812 (2007).
120. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 12(11), 1227-1233 (2000).
121. Oren R, Arber N, Odes et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110(5), 1416-1421 (1996).
122. Cummings JR, Herrlinger KR, Travis SP et al. Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther. 21(4), 385-389 (2005).
123. Paoluzi OA, Pica R, Marcheggiano A et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther. 16(10), 1751-1759 (2002).
124. Te HS, Schiano TD, Kuan SF et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 95(11), 3150-3156 (2000).
125. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J. Pediatr. 132(5), 830-835 (1998).
126. Stephens MC, Baldassano RN, York A et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J. Pediatr Gastroenterol. Nutr. 40(4), 445-449 (2005).
127. Sun JH, Das KM. Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand. J. Clin. Gastroenterol. 39(9), 751-756 (2005).
128. Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr. Drugs 8 (5), 279-302 (2006).
129. McDonald JW, Feagan BG, Jewell D et al. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2, CD000297 (2005).
130. Lichtenstein GF, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130(3), 940-987 (2006).
131. Mahdi G, Israel DMI Hassall E. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's coli tis in children. Am. J. Gastroenterol. 91(7), 1355-1359 (1996).
132. Lichtiger S, Present DH, Kombluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330(26), 1841-1845 (1994).
133. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125(4), 1025-1031 (2003).
134. Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr 22(3), 296-302 (1996).
135. Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis. Colon Rectum 38(5), 474-479 (1995).
136. Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig. Dis. Sci. 51(10), 1833-1840 (2006).
137. Gonzalez-Lama Y, Abreu L, Vera MI et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm. Bowel Dis. 11(1), 8-15 (2005).
138. Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125(2), 380-388 (2003).
139. Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm. Bowel Dis. 13(3), 245-253 (2007).
140. Bousvaros A, Kirschner BS, Werlin SL et al. Oral tacrolimus treatment of severe colitis in children. J. Pediatr. 137(6), 794-799 (2000).
141. Ziring DA, Wu SS, Mow WS et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J. Pediatr. Gastroenterol. Nutr. 45(3), 306-311 (2007).
142. Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106(6), 1455-1466 (1994).
143. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J. Clin. Pathol. 46(8), 757-760 (1993).
144. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs, 65(16), 2253-2286 (2005).
145. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029-1035 (1997).
146. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002).
147. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340(18), 1398-1405 (1999).
148. Akobeng AK, Zachos M. Tumor necrosis factor-α antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1, CD003574 (2004).
149. Baldassano R, Braegger CP, Escher JC et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 98(4), 833-838 (2003).
150. Cezard JP, Nouaili N, Talbotec C et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J. Pediatr. Gastroenterol. Nutr. 36(5), 632-636 (2003).
151. Kugathasan S. Prolonged duration of response to infliximab in early pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 33(Suppl. 1), S40-S43 (2001).
152. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132(3), 863-873 (2007).
153. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005).
154. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128(7), 1805-1811 (2005).
155. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. 38(3), 298-301 (2004).
156. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11(3), 213-218 (2005).
157. Fanjiang G, Russell GH, Katz AJ. Short-and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 44(3), 312-317 (2007).
158. Jacobstein DA, Markowitz JE, Kirschner BS et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. 11(5), 442-446 (2005).
159. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol. 4(10), 1248-1254 (2006).
160. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2(7), 542-553 (2004).
161. Rampton DS. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 54(10), 1360-1362 (2005).
162. Lichtenstein GF, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4(5), 621-630 (2006).
163. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 13(8), 1024-1030 (2007).
164. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130(2), 323-333 (2006).
165. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1), 52-65 (2007).
166. Sandborn WJ, Hanauer SB, Rutgeerts PJ et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56, 1232-1239 (2007).
167. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146(12), 829-838 (2007).
168. Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 41(3), 357-359 (2005).
169. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J. Gastroenterol. 13(16), 2328-2332 (2007).
170. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348 (1), 24-32 (2003).
171. Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132(5), 1672-1683 (2007).
172. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1, CD006097 (2007).
173. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353(18), 1912-1925 (2005).
174. Hyams JS, Wilson DC, Thomas A et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 44(2), 185-191 (2007).
175. Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to α-4 integrin. Aliment. Pharmacol. Ther. 16(4), 699-705 (2002).
176. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med. 353(4), 369-374 (2005).
177. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353(4), 375-381 (2005).
178. Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal. leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353(4), 362-368 (2005).
179. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924-933 (2006).
180. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegot (CDP870) for treatment of Crohn's disease. Gastroenterology 129(3), 807-818 (2005).
181. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007).
182. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357(3), 239-250 (2007).